China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in funding from Beijing E-town International Investment & Development Co., Ltd. The investment is designated to support the research and development of the company’s pipeline programs, including the KRAS G12C-targeted glecirasib and other key projects.
Jacobio’s Robust Pipeline and Intellectual Property
Founded in 2015, Jacobio has established a strong presence in the pharmaceutical industry with a dozen investigational programs and over 300 patents. The company’s commitment to innovation is further evidenced by clinical trials being conducted in more than 100 hospitals globally. Jacobio’s pipeline includes a range of promising drug candidates, with glecirasib (JAB-21822), an in-house developed KRAS G12C inhibitor, at the forefront.
Strategic Partnerships and Recent Developments
The company previously entered into a licensing agreement with AbbVie, which granted the US firm global rights to Jacobio’s SHP2 inhibitors JAB-3312 and JAB-3068. However, this USD 866 million deal was canceled in July of this year. Despite this setback, Jacobio continues to make significant strides with glecirasib, which has recently become the first KRAS G12C inhibitor to enter a pivotal study in pancreatic cancer on a global scale, highlighting its potential in treating advanced solid tumors in China, the US, and Europe.-Fineline Info & Tech
